RxDoctor Payments Data

Manuel Palafox, DO

Internal Medicine · El Paso, TXNPI 1952301137

Payments from drug & device makers

$849in general payments, 2019–2025

Across 29 payments — averaging $29.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$318
  • Astellas Pharma US Inc$169
  • Saxum Surgical, Inc.$138
  • AbbVie$106
  • Boehringer Ingelheim$32
  • Lilly USA, LLC$32
  • plus $53 from 3 others

What the payments were for

  • Food & beverage$849100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$849 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$11,556
Medicare patients
50
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin228$347,368
Bydureon BciseExenatide Microspheres126$247,003
JanuviaSitagliptin Phosphate158$243,271
TrulicityDulaglutide81$129,079
EliquisApixaban72$89,523
OzempicSemaglutide61$79,589
MounjaroTirzepatide39$61,239
MyrbetriqMirabegron41$50,877
XareltoRivaroxaban24$45,528
LinzessLinaclotide34$43,398
Lantus SolostarInsulin Glargine,hum.Rec.Anlog196$42,462
JanumetSitagliptin Phos/Metformin Hcl34$41,805
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog33$32,356
ProliaDenosumab14$24,451
TradjentaLinagliptin14$23,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$32$370,389242 claims
Lilly USA, LLCTrulicity, Mounjaro$32$190,318120 claims
Astellas Pharma US IncMyrbetriq$169$50,87741 claims
AbbVieLinzess$106$43,39834 claims
Sanofi-aventis U.S. LLCLantus$18$5,47628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →